Boston, MA 06/04/2013 (wallstreetpr) – The shares of Receptos Inc. (NASDAQ:RCPT) had surged in their prices by 15.69 percent to close at $18.36 per share for the end of last trading session on Monday. The shares of the company had been trading in the range of $15.96 to $25.00 per share during the day. The recent surge in share prices of Receptos Inc. (NASDAQ:RCPT) had led the company to hit new peak of 52 week high prices at $25.00 per share, while the 52 week low price level of shares of the company is at $13.00 per share.
Receptos Inc. (NASDAQ:RCPT) is involved in the research, development, production and commercialization of treatment therapies for immune disorders. The product candidates of the bio pharmaceutical company had been designed to cover three disease areas related to immune disorders. Receptos Inc. (NASDAQ:RCPT) had been identified to possess strong development potential through its product candidates targeting two large markets and aimed for treating rare diseases related to immune disorders.
The recent clinical product candidates of Receptos Inc. (NASDAQ:RCPT) include RPC4046 and RPC 1063. While RPC1063 is being tested for treatment of relapsing multiple sclerosis and inflammatory bowel disease, the RPC4046 is to be used for the treatment of a rare disease Eosinophilic Esophagitis, both with strong potential to provide first in class treatments. . The trading volume of Receptos Inc. (NASDAQ:RCPT) on Monday was observed to be 60,142 shares while the average trading volume of the pharmaceutical company is at 119,889 shares per day. The company presently has 17.10 million shares outstanding in the market.
